FORWARD FEATURES CALENDAR

Funds

Audax Private Equity completes sale of Preferred Compounding to HEXPOL

Audax Private Equity (Audax), in partnership with management, has completed the sale of Preferred Compounding Corporation (Preferred Compounding) to HEXPOL (STO:HPOL-B). Headquartered in Copley, OH, Preferred is a leading provider of proprietary and custom mixed rubber compounds, including strips, slabs, pellets, and calendered sheet end forms. The Company maintains relationships

Incline Equity Partners closes on USD314.5m for new fund platform

Sixpoint Partners has announced the successful closing of Incline Elevate Fund with USD314.5 million of total capital commitments. The Fund, which is the fifth investment vehicle and first fund extension vehicle for Incline Equity Partners (Incline), easily surpassed its initial hard cap of USD300 million after only two months of

Inverness Graham raises USD415m for latest fund

Inverness Graham Investments, a lower middle market private investment firm, has raised USD415 million for Inverness Graham Investments IV (IGI-IV), eclipsing its USD300 million target and meeting its hard cap in less than four months. The firm did not use a placement agent. IGI-IV will continue its strategy of acquiring high

Core Industrial’s portfolio company Protek acquires Cal-X

Chicago-based private equity firm CORE Industrial Partners’ (CORE) portfolio company Prototek has acquired Cal-X, a provider of precision machining and sheet metal fabrication rapid prototyping services.  Financial terms of the transaction have not been disclosed.   Headquartered in Wisconsin, Cal-X offers rapid prototyping and short-run production services through its wide

Signavio raises USD177m led by Apax Digital

Signavio, a provider of business transformation solutions, has announced a USD177 million investment to fuel continued international expansion and further investment in its world-class software suite.  The transaction was led by Apax Digital, the growth equity team of Apax Partners, with participation from DTCP. Existing investor Summit Partners will retain an

Maven & NPIF invests GBP900,000 in ebb3

Maven Capital Partners (Maven), has led a GBP900,000 investment in supercomputing technology specialist, ebb3 Limited (ebb3’).  A total of GBP750,000 was invested by NPIF – Maven Equity Finance (NPIF), managed by Maven and part of the Northern Powerhouse Investment Fund, with a further GBP150,000 provided by the Maven VCTs.  The

National fund manager FDC relocates HQ to Birmingham’s business district

Frontier Development Capital (FDC), an established fund manager operating debt funds in England, has relocated its Birmingham headquarters. The firm has moved its operations and 25 staff from Baskerville House to a 5,246 sq ft office on 45 Church Street in the heart of the city’s business district.   FDC

Kempen European Private Equity Fund acquires interest in Wilvo Group

The Kempen European Private Equity Fund has acquired a significant direct interest in Wilvo Group a family business in the province of Brabant in the Netherlands that specialises in the processing of thin sheet metal and precision parts assembly.  Wilvo Group employs 230 people and has an annual turnover of

vasopharm closes EUR9.5m financing round

vasopharm, a private biopharmaceutical company developing a new treatment for traumatic brain injury (TBI), has completed a EUR9.5 million financing co-led by HeidelbergCapital Private Equity and EF Investments.  Existing investors Bayern Kapital, Future Capital, clients of Hanseatic Asset Management and Ringtons Holdings also participated in the round. In addition, vasopharm

Keensight Capital acquires 3P Biopharmaceuticals

Private equity manager Keensight Capital has acquired Infarco’s majority stake in 3P Biopharmaceuticals, a Contract Development and Manufacturing Organisation (CDMO) specialised in the process development and GMP manufacturing of biologics. Founded in 2006 and based near Pamplona, Spain, 3P Biopharmaceuticals offers a complete biologics production service, from preclinical and clinical

Events

12 November, 2026 – 5:00 pm

Directory Listings